Enomark Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 30-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 30-11-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 Cr
as on 30-11-2024
- Revenue -100.00%
(FY 2023)
- Profit -1146.10%
(FY 2023)
- Net Worth 1302.02%
(FY 2023)
- Total Assets 3721.02%
(FY 2023)
About Enomark Pharma
The Corporate was formerly known as Aerozest Life Science Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹7.50 Cr.
Shriram Patel, Umesh Patel, Laxmanram Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909MH2016PTC282093
- Company No.
282093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Enomark Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shriram Patel  | Managing Director | 21-Jan-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umesh Patel | Director | 21-Jan-2022 | Current |
| Laxmanram Patel | Director | 30-Sep-2023 | Current |
| Jetharam Patel | Director | 14-Jun-2024 | Current |
Financial Performance of Enomark Pharma.
Enomark Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 1146.1% decrease in profit. The company's net worth Soared by an impressive increase of 1302.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Enomark Pharma?
In 2023, Enomark Pharma had a promoter holding of 100.00%. The company had 3 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Karkinos Lifescience Private LimitedActive 1 year 11 monthsShriram Patel and Laxmanram Patel are mutual person
- Medicopia Pharma Private LimitedActive 2 years 2 months
Shriram Patel and Laxmanram Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Mar 2024 | ₹7.50 Cr | Open |
How Many Employees Work at Enomark Pharma?
Unlock and access historical data on people associated with Enomark Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enomark Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enomark Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
